Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers. (2nd November 2021)

• Record Type: Journal Article
• Authors: Arakaki, Aleena K S; Szulzewsky, Frank; Gilbert, Mark R; Gujral, Taranjit S; Holland, Eric C
• Is Part Of: Neuro-oncology. Volume 23: Supplement 5(2021)
• Page Start: S4
• Page End: S15
• Publication Date: 2021-11-02
• Subjects: atypical teratoid rhabdoid tumors -- diffuse midline glioma -- ependymoma -- preclinical cancer models -- rare cancers; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab183
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Patients with rare central nervous system (CNS) tumors typically have a poor prognosis and limited therapeutic options. Historically, these cancers have been difficult to study due to small number of patients. Recent technological advances have identified molecular drivers of some of these rare cancers which we can now use to generate representative preclinical models of these diseases. In this review, we outline the advantages and disadvantages of different models, emphasizing the utility of various in vitro and ex vivo models for target discovery and mechanistic inquiry and multiple in vivo models for therapeutic validation. We also highlight recent literature on preclinical model generation and screening approaches for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors, all of which are rare CNS cancers that have recently established genetic or epigenetic drivers. These preclinical models are critical to advancing targeted therapeutics for these rare CNS cancers that currently rely on conventional treatments.